AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 201 min read$HTFL

Rogers Campbell sold $380K of HTFL

Rogers Campbell (Chief Medical Officer) sold 9,219 shares of Heartflow, Inc. (HTFL) at $41.23 ($0.38M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rogers Campbell
Published Aug 20, 2026, 1:04 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HTFL
Neutral
medium confidence
Mentioned
$HTFL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HTFLNeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary source.

02

Market read

Small insider sale, likely limited market impact but worth noting for short‑term traders.

03

What to watch

Potential upcoming clinical trial results could outweigh the impact of this insider sale.

Relevance 3/10Novelty 4/10Timing: filed after market close on 2026-08-19

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$HTFLNeutralMedium confidence
Context

Chief Medical Officer Rogers Campbell sold 9,219 shares for $380,099 via a 10b5-1 plan, reducing his stake to 86,459 shares.

Expected impact

Minor downward pressure, potential short-term dip.

Evidence & confidence

Sale amount under $1M and executed under a pre‑arranged plan; market may view as routine.

Market effects

Sector

None significant for the broader healthcare sector.

Regional

Limited to US biotech investors.

Global

Minimal.

Counterpoint

What could challenge this read

The sale could be a signal of upcoming negative news not yet public.

Key entities

  • Company
    Heartflow, Inc.

    Medical device company developing non‑invasive coronary artery disease diagnostics.

  • Person
    Rogers Campbell

    Chief Medical Officer of Heartflow.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HTFL insider trading history →

Related articles

AUG 19
$HTFLMedAI 8/10

Why Heartflow Stock Soared Today

HeartFlow (HTFL) shares rose after the company raised its full-year revenue targets. Revenue grew 48% YoY to $64.1M in Q2, with adjusted gross margin increasing to 83.3%. The company now expects 40-42% revenue growth for 2026, up from prior forecasts. CEO John Farquhar cited improved operating leverage and scalability.

aol.com2 min
AUG 15
$HTFLMedAI 8/10

Analysts Are Bullish on Heartflow (HTFL) Stock. Here’s Why

Heartflow Inc. (NASDAQ:HTFL) hit a new all-time high after reporting Q2 revenue growth of 48% to $64.08 million from $43.2 million. The company raised full-year revenue guidance to 40% to 42% growth, targeting $246 million to $250 million. Net loss widened to $15.7 million. Analysts at Stifel and JPMorgan raised price targets to $45.

yahoo.com4 min